Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Trading Update

5 Feb 2010 07:00

RNS Number : 7246G
China Real Estate Opportunities PLC
05 February 2010
 



 

 

 

China Real Estate Opportunities plc

 

Pre-Close Trading Update

 

China Real Estate Opportunities plc (the "Company"), one of the leading Chinese property companies quoted on the AIM market of the London Stock Exchange, has issued the following trading update in advance of the release of its annual results for the 12 month period ended 31 December 2009.

 

Property Portfolio Valuation as at 31 December 2009

 

The Board is pleased to announce that as at 31 December 2009 the aggregate gross value of the portfolio, as determined by an independent valuation carried out by DTZ Debenham Tie Leung in accordance with RICS standards, was RMB9.188 billion (equivalent to £837 million at the closing exchange rate of RMB10.98:£1 as at 31 December 2009). These valuations are broken down as follows:

 

Name

31 December 2009

30 June 2009

RMB million

RMB million

City Centre, Shanghai

5,564

5,390

City Centre Extension, Shanghai

1,261

1,213

Central Plaza, Shanghai

1,604

1,532

The Treasury Building, Shanghai

641

600

Beijing International Logistics Centre, Beijing

118

 

99

Total

9,188

8,834

 

These valuations, which are based on fair values in accordance with the Company's normal accounting policies, represent an increase of 4% in local currency terms (7.35% in sterling terms) since the 30 June 2009 valuation of RMB8.834 billion (equivalent to £780 million at the then prevailing exchange rate of RMB11.25:£1). These amounts exclude the recent disposal of the Company's interest in the Tangdao Bay property, the proceeds of which will be received upon completion of the standard PRC regulatory procedures for the offshore repatriation of proceeds of domestic asset sales.

 

Trading Update

The year just ended proved to be a challenging year on the office leasing front with vacancy rates in Shanghai peaking at 14.2% in Q1 and reducing to 11.4% by year end. The retail sector however, continued to perform strongly, aided by the resurgence of the Chinese consumer.

 

The property portfolio witnessed 212 lease expiries during the year, representing more than 50% of its entire tenancy base. Approximately 55% of these leases were renewed, whilst a further 15% were moved out of the Central Plaza property as part of the refurbishment and re-positioning program. Sixty new tenants, amounting to 28% of lease expiries, entered into leases including Metlife Insurance, Prudential Insurance and Johnson & Johnson. Overall, this resulted in portfolio occupancy (excluding space under refurbishment) at 31 December 2009 of 85%, (office 79%; retail 97%) representing a reduction of 6% over 31 December 2008 but translated into increases in gross rental income on a per square metre basis as follows:

 

Average daily rent per sqm (RMB)

Investment Property

31 December 2009

30 June 2009

Increase over period

City Centre Office

5.32

5.05

5%

City Centre Retail

6.11

5.97

2%

Central Plaza

6.33

6.16

3%

Treasury Building

6.18

6.18

0%

 

As previously reported, during the year, two disposals have been made at premia to the values at which they had been included in the financial statements. These were the 5% interest in City Centre 5, disposed of in June 2009 for an 8.9% premium over the valuation at 31 December 2008 and the 50% interest in Tangdao Bay, disposed of in January 2010 for a 10.9% premium over the valuation at 30 June 2009. In addition, the disposal in November 2009 of approximately 60% of the Company's shareholding in RREEF China Commercial Trust, a Hong Kong listed entity, generated a 20% return on acquisition price.

 

Including the proceeds from the Tangdao Bay disposal, the Company's cash holdings at 31 December 2009 would have amounted to approximately £75 million.

 

The Company also made significant progress in the first phase of its refinancing programme with the completion of a loan facility with CITIC Ka Wah Bank in December 2009. This replaced, on improved terms, the existing loan with Credit Suisse in respect of the Treasury Building in Shanghai, which had been due to expire in March 2010. From discussions taking place, the Company remains confident that significant interest remains from a number of local and regional banks to fulfill the Company's refinancing requirements in 2010.

 

 Asian listing

Despite this strong performance in a difficult global environment, the Company's shares continue to trade at a significant discount to net asset value. With a view to narrowing the gap, the Board, with its advisers, has been considering for some time a number of options intended to widen the universe of potential shareholders, including obtaining a listing for the Company on a recognised stock exchange in Asia, so as to deliver the following potential benefits:

 

Ø Positioning the company closer to its asset base

Ø Strong regional appreciation for Chinese real estate companies which in the main trade at a very low discount or slight premium to NAV

Ø Ability to participate in the strong capital flows experienced in Asia, which have exceeded USD8.8 billion for the property sector on the Hong Kong and Singapore exchanges alone in the past 6 months

 

More specifically, the Board has identified Singapore as its preferred listing location and a "Business Trust" structure under Singapore law as the likely structure, and subject to ongoing communication with shareholders and the relevant regulators, the Company intends to proceed with this proposal within the next 6 months.

 

Singapore Business Trusts provide greater operational and investment flexibility than Real Estate Investment Trusts with regard to matters such as development limits and levels of gearing. This flexibility should enable CREO to deliver stronger growth and higher accretive earnings than its peer group.

 

The Company intends to engage with its shareholders to elicit their feedback on this proposal, which is at an advanced exploratory stage.

 

Tender Offer

The Company expects to receive the sales proceeds from its disposal of Tangdao Bay upon completion of the standard PRC regulatory procedures for the offshore repatriation of proceeds of domestic asset sales and CREO will make a further announcement regarding the proposed tender offer in due course.

 

Contact:

 

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

 

Sarah Moriarty, Investor Relations

Tel: +353 1 6189455

 

Matrix Corporate CapitalPaul Fincham Tel +44 (0)20 3206 7000

Davy

Des Carville

Tel: +353 1 679 6363

 

Citigate Dewe Rogerson Limited

Tom Baldock

Tel: + 44 (0) 20 7638 9571

 

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKKQDNOBKDKBK
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.